Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. / Stephens, J W; Bodvarsdottir, T B; Wareham, K; Prior, S L; Bracken, R M; Lowe, G D; Rumley, A; Dunseath, G; Luzio, S; Deacon, C F; Holst, Jens Juul; Bain, S C.

In: Diabetes Research and Clinical Practice, Vol. 94, No. 2, 11.2011, p. 199-206.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stephens, JW, Bodvarsdottir, TB, Wareham, K, Prior, SL, Bracken, RM, Lowe, GD, Rumley, A, Dunseath, G, Luzio, S, Deacon, CF, Holst, JJ & Bain, SC 2011, 'Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus', Diabetes Research and Clinical Practice, vol. 94, no. 2, pp. 199-206. https://doi.org/10.1016/j.diabres.2011.07.014

APA

Stephens, J. W., Bodvarsdottir, T. B., Wareham, K., Prior, S. L., Bracken, R. M., Lowe, G. D., Rumley, A., Dunseath, G., Luzio, S., Deacon, C. F., Holst, J. J., & Bain, S. C. (2011). Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 94(2), 199-206. https://doi.org/10.1016/j.diabres.2011.07.014

Vancouver

Stephens JW, Bodvarsdottir TB, Wareham K, Prior SL, Bracken RM, Lowe GD et al. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 2011 Nov;94(2):199-206. https://doi.org/10.1016/j.diabres.2011.07.014

Author

Stephens, J W ; Bodvarsdottir, T B ; Wareham, K ; Prior, S L ; Bracken, R M ; Lowe, G D ; Rumley, A ; Dunseath, G ; Luzio, S ; Deacon, C F ; Holst, Jens Juul ; Bain, S C. / Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. In: Diabetes Research and Clinical Practice. 2011 ; Vol. 94, No. 2. pp. 199-206.

Bibtex

@article{3d9d350890f64ffdbca13bce37cea396,
title = "Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus",
abstract = "Aim: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin. Methods: A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120). Results: Significant improvements in glucose were observed with repaglinide (HBA1c: 1.5%, fasting glucose: 2.8 mmol/L, 2-h glucose: 3.7 mmol/L, AUC120: 18.9%) and glibenclamide (1.0%, 2.2 mmol/L, 2.5 mmol/L, 17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress. Conclusion: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.",
keywords = "Adult, Aged, Analysis of Variance, Biological Markers, Blood Glucose, Carbamates, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, E-Selectin, F2-Isoprostanes, Female, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Glyburide, Hemoglobin A, Glycosylated, Humans, Hyperglycemia, Hypoglycemic Agents, Incretins, Insulin, Intercellular Adhesion Molecule-1, Interleukin-6, Male, Metformin, Middle Aged, Oxidative Stress, Piperidines, Postprandial Period, Time Factors, Treatment Outcome, Wales",
author = "Stephens, {J W} and Bodvarsdottir, {T B} and K Wareham and Prior, {S L} and Bracken, {R M} and Lowe, {G D} and A Rumley and G Dunseath and S Luzio and Deacon, {C F} and Holst, {Jens Juul} and Bain, {S C}",
note = "Copyright {\textcopyright} 2011 Elsevier Ireland Ltd. All rights reserved.",
year = "2011",
month = nov,
doi = "10.1016/j.diabres.2011.07.014",
language = "English",
volume = "94",
pages = "199--206",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus

AU - Stephens, J W

AU - Bodvarsdottir, T B

AU - Wareham, K

AU - Prior, S L

AU - Bracken, R M

AU - Lowe, G D

AU - Rumley, A

AU - Dunseath, G

AU - Luzio, S

AU - Deacon, C F

AU - Holst, Jens Juul

AU - Bain, S C

N1 - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

PY - 2011/11

Y1 - 2011/11

N2 - Aim: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin. Methods: A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120). Results: Significant improvements in glucose were observed with repaglinide (HBA1c: 1.5%, fasting glucose: 2.8 mmol/L, 2-h glucose: 3.7 mmol/L, AUC120: 18.9%) and glibenclamide (1.0%, 2.2 mmol/L, 2.5 mmol/L, 17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress. Conclusion: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.

AB - Aim: To examine the effects of glibenclamide and repaglinide on glucose stimulated insulin release, incretins, oxidative stress and cell adhesion molecules in patients with type 2 diabetes suboptimally treated with metformin. Methods: A randomized clinical trial was performed recruiting 27 subjects (HbA1c between 7.5 and 10.5%) free from cardiovascular and renal disease. Glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), total antioxidant status, F2-isoprostane, interleukin-6 and cell adhesion molecules were measured during an oral glucose load at baseline and after eight weeks of treatment. The areas under the curve were analysed at 45, 60 and 120 min (AUC45, AUC60, AUC120). Results: Significant improvements in glucose were observed with repaglinide (HBA1c: 1.5%, fasting glucose: 2.8 mmol/L, 2-h glucose: 3.7 mmol/L, AUC120: 18.9%) and glibenclamide (1.0%, 2.2 mmol/L, 2.5 mmol/L, 17.5%). Repaglinide was also associated with an increase in the AUC60 and AUC120 for insulin (+56%, +61%) and C-peptide (+41%, +36%). GLP-1, GIP, IL-6, ICAM-1 and E-selectin levels did not change in either group. No association was observed between GLP-1, GIP-1 and plasma markers of oxidative stress. Conclusion: Repaglinide is associated with improved postprandial glycaemic control via insulin and C-peptide release. We observed no direct effects of glibenclamide or repaglinide on plasma levels of GLP-1 or GIP. We observed no associations of GLP-1 and GIP with plasma markers of oxidative stress.

KW - Adult

KW - Aged

KW - Analysis of Variance

KW - Biological Markers

KW - Blood Glucose

KW - Carbamates

KW - Diabetes Mellitus, Type 2

KW - Drug Administration Schedule

KW - Drug Therapy, Combination

KW - E-Selectin

KW - F2-Isoprostanes

KW - Female

KW - Gastric Inhibitory Polypeptide

KW - Glucagon-Like Peptide 1

KW - Glyburide

KW - Hemoglobin A, Glycosylated

KW - Humans

KW - Hyperglycemia

KW - Hypoglycemic Agents

KW - Incretins

KW - Insulin

KW - Intercellular Adhesion Molecule-1

KW - Interleukin-6

KW - Male

KW - Metformin

KW - Middle Aged

KW - Oxidative Stress

KW - Piperidines

KW - Postprandial Period

KW - Time Factors

KW - Treatment Outcome

KW - Wales

U2 - 10.1016/j.diabres.2011.07.014

DO - 10.1016/j.diabres.2011.07.014

M3 - Journal article

C2 - 21835486

VL - 94

SP - 199

EP - 206

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -

ID: 38186756